Tβ4-17 peptide enhances the chemo-sensitivity of ovarian cancer cells to DDP by affecting NF-κB signaling pathway.

Guo L, Wang H, Li N, Wang J, Yu M, Li Y, Yan P, Su Y, Teng L

Medical oncology (Northwood, London, England)8 Nov 2025

PMID41205079PMCIDPMC12596292DOI10.1007/s12032-025-03106-4PepBankPUB-41205079

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

01LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Efficacy outcome
Tβ4-17 peptide combined with cisplatin (DDP) significantly inhibited the proliferation of drug-resistant ovarian cancer cells.
In plain wordsIn cells, the Tβ4-17 fragment together with cisplatin slowed the multiplication of drug-resistant ovarian cancer cells.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseProliferation of drug-resistant ovarian cancer cells
Study
n: not reported in source
DDP-resistant ovarian cancer cells
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Our results showed that Tβ4-17 peptide combined with DDP significantly inhibited the proliferation and migration of drug resistance cells in ovarian cancer, promoted apoptosis, and increased the chemo-sensitivity of ovarian cancer cells to DDP.
1 context sentence(design, population, supporting numbers)
Summary · context
This study mainly investigated its effect in combination with cisplatin (DDP) on the proliferation, migration and apoptosis of ovarian cancer resistant cells and related molecular mechanisms.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-4120507901
02LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Efficacy outcome
Tβ4-17 peptide combined with DDP significantly inhibited the migration of drug-resistant ovarian cancer cells.
In plain wordsIn cells, the Tβ4-17 fragment together with cisplatin reduced the movement of drug-resistant ovarian cancer cells.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseMigration of drug-resistant ovarian cancer cells
Study
n: not reported in source
DDP-resistant ovarian cancer cells
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Our results showed that Tβ4-17 peptide combined with DDP significantly inhibited the proliferation and migration of drug resistance cells in ovarian cancer, promoted apoptosis, and increased the chemo-sensitivity of ovarian cancer cells to DDP.
1 context sentence(design, population, supporting numbers)
Summary · context
This study mainly investigated its effect in combination with cisplatin (DDP) on the proliferation, migration and apoptosis of ovarian cancer resistant cells and related molecular mechanisms.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-4120507902
03LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Efficacy outcome
Tβ4-17 peptide combined with DDP promoted apoptosis of drug-resistant ovarian cancer cells.
In plain wordsIn cells, the Tβ4-17 fragment together with cisplatin increased the death of drug-resistant ovarian cancer cells.
Peptide
Thymosin beta-4 (human)
Outcome
IncreaseApoptosis of drug-resistant ovarian cancer cells
Study
n: not reported in source
DDP-resistant ovarian cancer cells
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Our results showed that Tβ4-17 peptide combined with DDP significantly inhibited the proliferation and migration of drug resistance cells in ovarian cancer, promoted apoptosis, and increased the chemo-sensitivity of ovarian cancer cells to DDP.
1 context sentence(design, population, supporting numbers)
Summary · context
This study mainly investigated its effect in combination with cisplatin (DDP) on the proliferation, migration and apoptosis of ovarian cancer resistant cells and related molecular mechanisms.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-4120507903
04LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Efficacy outcome
Tβ4-17 peptide combined with DDP increased the chemo-sensitivity of ovarian cancer cells to DDP.
In plain wordsIn cells, the Tβ4-17 fragment made ovarian cancer cells more sensitive to cisplatin.
Peptide
Thymosin beta-4 (human)
Outcome
IncreaseChemo-sensitivity to DDP
Study
n: not reported in source
DDP-resistant ovarian cancer cells
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Our results showed that Tβ4-17 peptide combined with DDP significantly inhibited the proliferation and migration of drug resistance cells in ovarian cancer, promoted apoptosis, and increased the chemo-sensitivity of ovarian cancer cells to DDP.
1 context sentence(design, population, supporting numbers)
Summary · context
This study mainly investigated its effect in combination with cisplatin (DDP) on the proliferation, migration and apoptosis of ovarian cancer resistant cells and related molecular mechanisms.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-4120507904
05LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism
Tβ4-17 peptide down-regulated NF-κB p65 protein expression in DDP-resistant ovarian cancer cells.
In plain wordsIn cells, the Tβ4-17 fragment lowered NF-κB p65 protein in drug-resistant ovarian cancer cells.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseNF-κB p65 protein expression
Study
n: not reported in source
DDP-resistant ovarian cancer cells
Outcome group
Receptor activity and mechanism · Cancer
Source sentences
Summary
After application of NF-κB inhibitors and activators, Western blot, CCK8, EDU fluorescence proliferation assay, and cell scratch assay showed that Tβ4-17 peptide down-regulated NF-κB p65 protein expression and inhibited cell proliferation and migration.
1 context sentence(design, population, supporting numbers)
Summary · context
This study mainly investigated its effect in combination with cisplatin (DDP) on the proliferation, migration and apoptosis of ovarian cancer resistant cells and related molecular mechanisms.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-4120507905

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 01:52 UTC
Study results updated
Version 1
12 Oct 2026, 18:17 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.